Pharmaceutical Science Committee

FDA's Pharmaceutical Science Advisory Committee will meet Oct. 6 to discuss risk management for complex pharmaceuticals, bioequivalence for highly variable drugs, current thinking on nanotechnology, implementation of definitions for topical dosage forms and current strategies and future directions for the Critical Path initiative. On Oct. 5, the committee will hear presentations on quality-by-design by the Pharmaceutical Research & Manufacturers of America and Generic Pharmaceutical Association. [Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...